Emavusertib
Product Sizes
10 mg
£ POA
HY-135317-10MG
50 mg
£ POA
HY-135317-50MG
100 mg
£ POA
HY-135317-100MG
5 mg
£ POA
HY-135317-5MG
25 mg
£ POA
HY-135317-25MG
10mM/1mL
£ POA
HY-135317-10MM
About this Product
- SKU:
- HY-135317
- Additional Names:
- CA-4948
- CAS Number:
- 1801344-14-8
- Extra Details:
- Emavusertib is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib inhibits NF-κB and MyD88 signaling pathways; reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10; thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells; leading to cell apoptosis. Emavusertib exhibits antitumor activity in mouse model
- Molecular Weight:
- 491.50
- Purity:
- 99.97
- References:
- [1]Wiese MD, et al. Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2020 Apr 17:1-8.|[2]Guidetti F, et al. Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors. J Clin Med. 2023 Jan 4;12(2):399. |[3]Parrondo RD, et al. IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies. Front Immunol. 2023 Oct 26;14:1239082.
- Research Area:
- Cancer; Inflammation/Immunology
- Shipping Conditions:
- Ambient
- Storage Conditions:
- -20[o]C; 3 years; 4[o]C; 2 years (Powder)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- Apoptosis;Immunology/Inflammation;NF-κB;Protein Tyrosine Kinase/RTK
